Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Brief Communication
  • Published:

Acute myeloid Leukemia

Minimal residual disease (MRD) monitoring and mutational landscape in AML with RUNX1-RUNX1T1: a study on 134 patients

Leukemia volume 32, pages 2270–2274 (2018)Cite this article

Subjects

Access through your institution
Buy or subscribe

The cure rate in AML depends on patient’s age and performance status, cytogenetics, early blast clearance and sustainable first complete remission. Investigation of minimal residual disease (MRD) is possible by multiparameter-flow cytometry or molecular techniques. Recent findings have further depicted a broad spectrum of molecular markers in AML in 99% of patients [1]. This broadens the set of targets for MRD assessment and will hopefully help to better individualize treatment strategies. MRD monitoring by qPCR is feasible in AML with RUNX1-RUNX1T1 fusion. The absence of RUNX1-RUNX1T1 transcripts is considered as complete molecular remission (CMR). Risk stratification according to MRD is possible and initial studies allocating MRD positive patients to allogeneic stem cell transplantation have been undertaken [2]. However, despite CMR about 10–30% of patients relapse [3, 4].

This analysis aims to understand the clinical use of PCR based MRD monitoring in AML with RUNX1-RUNX1T1 fusion outside clinical trials. We specifically address chosen time points for measurements, choice of peripheral blood (PB) vs bone marrow (BM) as sample material for follow-up testing and evaluate the value of CMR as an absolute MRD negativity. In addition, we performed 63 gene panel sequencing to analyze recurrent mutations and their association to CMR and outcome.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2

References

  1. Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson A, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059–74.

    Article  PubMed  Google Scholar 

  2. Zhu HH, Zhang XH, Qin YZ, Liu DH, Jiang H, Chen H, et al. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood. 2013;121:4056–62.

    Article  CAS  PubMed  Google Scholar 

  3. Jourdan E, Boissel N, Chevret S, Delabesse E, Renneville A, Cornillet P, et al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood. 2013;121:2213–23.

    Article  CAS  PubMed  Google Scholar 

  4. Yin JA, O’Brien MA, Hills RK, Daly SB, Wheatley K, Burnett AK. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood. 2012;120:2826–35.

    Article  CAS  PubMed  Google Scholar 

  5. Weisser M, Haferlach C, Hiddemann W, Schnittger S. The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors. Leukemia. 2007;21:1177–82.

    Article  CAS  PubMed  Google Scholar 

  6. Faber ZJ, Chen X, Gedman AL, Boggs K, Cheng J, Ma J, et al. The genomic landscape of core-binding factor acute myeloid leukemias. Nat Genet. 2016;48:1551–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Duployez N, Marceau-Renaut A, Boissel N, Petit A, Bucci M, Geffroy S, et al. Comprehensive mutational profiling of core binding factor acute myeloid leukemia. Blood. 2016;127:2451–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Nucifora G, Larson RA, Rowley JD. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood. 1993;82:712–5.

    CAS  PubMed  Google Scholar 

  9. Pigazzi M, Manara E, Buldini B, Beqiri V, Bisio V, Tregnago C, et al. Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement. Haematologica. 2015;100:e99–101.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Allen C, Hills RK, Lamb K, Evans C, Tinsley S, Sellar R, et al. The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. Leukemia. 2013;27:1891–901.

    Article  CAS  PubMed  Google Scholar 

  11. Jahn N, Agrawal M, Bullinger L, Weber D, Corbacioglu A, Gaidzik VI, et al. Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22; q22): a study of the German-Austrian AML Study Group. Leukemia. 2017;31:1012–5.

    Article  CAS  PubMed  Google Scholar 

  12. Yamato G, Shiba N, Yoshida K, Shiraishi Y, Hara Y, Ohki K, et al. ASXL2 mutations are frequently found in pediatric AML patients with t(8;21)/ RUNX1-RUNX1T1 and associated with a better prognosis. Genes Chromosomes Cancer. 2017;56:382–93.

    Article  CAS  PubMed  Google Scholar 

  13. Micol JB, Duployez N, Boissel N, Petit A, Geffroy S, Nibourel O, et al. Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations. Blood. 2014;124:1445–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med. 2017;377:454–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Evans EK, Gardino AK, Kim JL, Hodous BL, Shutes A, Davis A, et al. A precision therapy against cancers driven by KIT/PDGFRA mutations. Sci Transl Med. 2017;2017:9.

    Google Scholar 

Download references

Acknowledgements

We thank all patients and clinicians for their participation in this study and all co-workers in our laboratory for their excellent technical assistance.

Author contributions

AH and TH designed the study. AH interpreted the data and wrote the manuscript. SJ, MM AF and NN did molecular analyses. TH was responsible for cytomorphologic analyses, CH for cytogenetic and FISH analyses and WK for immunophenotyping. All authors read and contributed to the final version of the manuscript.

Author information

Authors and Affiliations

  1. MLL Munich Leukemia Laboratory, Munich, Germany

    Alexander Höllein, Sabine Jeromin, Manja Meggendorfer, Annette Fasan, Niroshan Nadarajah, Wolfgang Kern, Claudia Haferlach & Torsten Haferlach

Authors
  1. Alexander Höllein
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Sabine Jeromin
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Manja Meggendorfer
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Annette Fasan
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Niroshan Nadarajah
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. Wolfgang Kern
    View author publications

    You can also search for this author inPubMed Google Scholar

  7. Claudia Haferlach
    View author publications

    You can also search for this author inPubMed Google Scholar

  8. Torsten Haferlach
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Torsten Haferlach.

Ethics declarations

Conflict of interest

AH, SJ, MM, AF, NN: Employment by MLL Munich Leukemia Laboratory; CH, WK, TH: Equity ownership of MLL Munich Leukemia Laboratory. CH, WK, and TH are part owners of the MLL Munich Leukemia Laboratory. AH, SJ, MM, AF and NN are employed by the MLL Munich Leukemia Laboratory.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Höllein, A., Jeromin, S., Meggendorfer, M. et al. Minimal residual disease (MRD) monitoring and mutational landscape in AML with RUNX1-RUNX1T1: a study on 134 patients. Leukemia 32, 2270–2274 (2018). https://doi.org/10.1038/s41375-018-0086-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-018-0086-0

This article is cited by

Search

Advanced search

Quick links